Eric Floyd

Eric A. Floyd is the founder of Neurogene, Inc. (New York).
Dr. Floyd is currently a Director at Advent Therapeutics, Inc. and a Trustee at Meharry Medical College since 2010.
Former positions include Chief Executive Officer & Principal at Floyd Regulatory Strategic Consulting Group LLC; Chairman at Virpax Pharmaceuticals, Inc. from 2023 to 2024; Director at Scilex Pharmaceuticals, Inc. from 2014 to 2016; Vice President-Worldwide Regulatory Affairs at Cephalon, Inc.; Global Vice President-Regulatory Affairs at Hospira, Inc.; Vice President & Global Head-Respiratory at Novartis AG; Senior Vice President-US Regulatory Affairs at Lundbeck, Inc.; CSO & President-Compliance Services at Eversana Life Science Services LLC; Assistant Professor at Harvard Medical School; Global Head-Regulatory Affairs at Axovant Sciences, Inc. from 2018 to 2019; Senior VP-Regulatory Affairs & Quality Assurance at Silence Therapeutics Plc from 2020 to 2025; Head-Regulatory Affairs at Merck & Co., Inc.; and Head-Regulatory Affairs at Aventis.
Education includes graduate studies at Tennessee State University, an MBA from St. Joseph's University, undergraduate studies at the University of Illinois, a doctorate from Meharry Medical College, and an MBA from Insead Business School.